Line 1: | Line 1: | ||
{{Hannover}} | {{Hannover}} | ||
<html> | <html> | ||
− | |||
− | |||
− | |||
− | |||
− | |||
<body> | <body> | ||
Line 27: | Line 22: | ||
<li><a href="https://2016.igem.org/Team:Hannover/Description">Description</a></li> | <li><a href="https://2016.igem.org/Team:Hannover/Description">Description</a></li> | ||
<li><a href="https://2016.igem.org/Team:Hannover/Design">Design</a></li> | <li><a href="https://2016.igem.org/Team:Hannover/Design">Design</a></li> | ||
+ | <!--li><a href="???">Modelling</a></li--> | ||
<li><a href="https://2016.igem.org/Team:Hannover/Demonstrate">Demonstrate</a></li> | <li><a href="https://2016.igem.org/Team:Hannover/Demonstrate">Demonstrate</a></li> | ||
<li><a href="https://2016.igem.org/Team:Hannover/Proof">Proof</a></li> | <li><a href="https://2016.igem.org/Team:Hannover/Proof">Proof</a></li> | ||
Line 41: | Line 37: | ||
<div id="collapseSW" class="panel-collapse collapse in"> | <div id="collapseSW" class="panel-collapse collapse in"> | ||
<ul class="list-group"> | <ul class="list-group"> | ||
− | <li><a href="https://2016.igem.org/Team:Hannover/Software">Description</a></li> | + | <li><a href="https://2016.igem.org/Team:Hannover/Software#description">Description</a></li> |
− | <li><a href=" | + | <li><a href="https://2016.igem.org/Team:Hannover/Software#phabricator">Phabricator</a></li> |
− | <li><a href=" | + | <li><a href="https://2016.igem.org/Team:Hannover/Software#modeling">Modeling: Programming a Chip Spotter</a></li> |
− | <li><a href=" | + | <li><a href="https://2016.igem.org/Team:Hannover/Software#talsetter">TALsetter</a></li> |
− | <li><a href="TODO">Design</a></li> | + | <!--li><a href="TODO">Design</a></li--> |
<!--li>Modelling</li--> | <!--li>Modelling</li--> | ||
</ul> | </ul> | ||
Line 56: | Line 52: | ||
</div> | </div> | ||
</div> | </div> | ||
− | |||
</div> | </div> | ||
+ | </div> | ||
</div> | </div> | ||
<div class="col-sm-8 text-left main-content"> | <div class="col-sm-8 text-left main-content"> |
Revision as of 19:36, 19 October 2016
References
- Boch, J. (2011). TALEs of genome targeting. Nature Biotechnology , 29 (2), pp. 135-136.
- Boch, J. et al. (2009). Breaking the Code of DNA Binding Specificity of TAL-Type III Effectors. Science (326), pp. 1509-1512.
- Boch, J. et al. (2009). Breaking the Code of DNA Binding Specificity of TAL-Type III Effectors. Science (326), pp. 1509-1512.
- Camarero, J. A., Fushman, D., Cowburn, D. & Muir, T. W. (2001). Peptide Chemical Ligation Inside Living Cells: In Vivo Generation of a Circular Protein Domain. Bioorganic & Medicinal Chemistry, pp. 2479-2484.
- Camarero, J. A., Fushman, D., Cowburn, D. & Muir, T. W. (2001). Peptide Chemical Ligation Inside Living Cells: In Vivo Generation of a Circular Protein Domain. Bioorganic & Medicinal Chemistry, pp. 2479-2484.
- Evans, T. C., Benner, J. & Xu, M.-Q. (1999). The Cyclization and Polymerisation of Bacterially Expressed Proteins Using Modified Self-splicing Inteins. The Journal of Biological Chemistry, 274 (26), pp. 18359-18363.
- Geissler, R. et al. (2011). Transcriptional Activators of Human Genes with Programmable DNA-Specificity. PLOS one.
- Hirschler, B. (2016, May). Second baby gets Cellectis "designer" cells to clear leukemia. Retrieved 10 13, 2016, from Reuters: http://www.reuters.com/article/us-health-celltherapy-idUSKCN0XX1F7
- Iwai, H., Lingel, A. & Plückthun, A. (2001). Cyclic Green Fluorescent Protein Produced in Vivo Using an Artificially Split PI-PfuI Intein from Pyrococcus furiosus. The Journal of Biological Chemistry, 276 (19), pp. 16548-16554.
- iGEM Team Heidelberg (2014). The Ring of Fire. Retrieved 10 13, 2016, from CIRCULARIZATION - Transforming an enzyme into a ring of fire: https://2014.igem.org/Team:Heidelberg/Toolbox/Circularization
- Lonzaric, J. et al. (2016). Locked and proteolysis-based transcription activator-like effector (TALE) regulation. Nucleic Acids Research, 44 (3), pp. 1471-1481.
- Miller, J. et al. (2011). A TALE nuclease architecture for efficient genome editing. Nature Biotechnology, 29 (2), pp. 143-148.
- Muir, T. W. (2003). Semisynthesis of proteins by expressed protein ligation. Annu. Rev. Biochem. (72), pp. 249-289.
- Office, G.-I. P. (2015, September). World first use of gene-edited immune cells to treat ‘incurable’ leukemia. Retrieved 10 13, 2016, from Great Ormond Street Hospital for Children: http://www.gosh.nhs.uk/news/press-releases/2015-press-release-archive/world-first-use-gene-edited-immune-cells-treat-incurable-leukaemia
- Qasim, W. et al. (2015). First Clinical Application of Talen Engineered Universal CAR19 T Cells in B-ALL. Blood , 126 (23), p. 2046.
- Specter, M. (2016, August). How the DNA Revolution Is Changing Us. Retrieved 10 13, 2016, from National Geographic: http://www.nationalgeographic.com/magazine/2016/08/dna-crispr-gene-editing-science-ethics/
- Streubel, J. et al. (2013). TALEs - Proteine mit programmierbarer DNA-Bindespezifität. BIOspektrum , 2013 (4), pp. 370-373.
- Tavassoli, A. & Benkovic, S. J. (2007). Split-intein mediated circular ligation use in the synthesis of cyclic peptide libraries in E. coli. Nature Protocols, 2 (5), pp. 1126-1133.
- Weber, E. et al. (2011). Assembly of Designer TAL Effectors by Golden Gate Cloning. PloS One, 6 (5).
- Williams, N. K. (2002). In Vivo Protein Cyclization Promoted by a Circularly Permuted Synechocystis sp. PCC6803 DnaB Mini-intein. The Journal of Biological Chemistry, 227 (10), pp. 7790-7798.
- Wood, D. W. & Camarero, J. A. (2014). Intein Applications: From Protein Purification and Labeling to Metabolic Control Methods. The Journal of Biological Chemistry, 289 (21), pp. 14512-14519.